New Delhi: Facing heightened dependence on Chinese API imports , the government’s move of setting minimum import price (MIP) on select inputs is likely to support the industry transition towards local souring and strengthen the country’s health security , the Indian Pharmaceutical Alliance (IPA) said. Last week, acting on industry concerns over Chinese predatory pricing, the Director General of Trade Remedies (DGTR) issued a notification announcing, "minimum import price" on certain key APIs and

MILAN & HYOGO, Japan--(BUSINESS WIRE)--Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), today announced an exclusive licensing agreement for the development and commercialisation of givinostat in Japan. Under the terms of the agreement, JCR receives exclusive rights to commercialise givinostat for the treatment of Duchenne muscular dystrophy (DMD) in Japan and will be responsible for the local execution of clinical development activities, as well as regulatory submissions.

Ahmedabad: Zydus Lifesciences , wholly owned subsidiary Zydus Lifesciences Global FZE, United Arab Emirates (UAE) has secured US commercial rights of Bioeq ’s macular degeneration biosimilar therapy Nufymco. The in-licensed drug is an interchangeable biosimilar to Lucentis and has been approved by U.S. Food and Drug Administration (USFDA) on December 18, 2025. Lucentis (Ranibizumab) marketed by Roche’s subsidiary Genentech, is a Vascular Endothelial Growth Factor (VEGF) inhibitor, used to trea

The FDA approved Agios Pharmaceuticals’ drug mitapivat to treat thalassemia on Tuesday, under the name Aqvesme, following a three-month delay and a missed deadline. The approval marks a key step forward for Agios as it looks to expand the drug’s use in blood disorders. Mitapivat was first approved as Pyrukynd in 2022 for adults with PK deficiency, and Agios plans on filing an FDA submission next year in sickle cell disease despite mixed Phase 3 results . Together with thalassemia, Agios has said

Sanofi is to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. The deal is the French drugmaker’s largest since it bought Blueprint Medicines for $9.1 billion in June. Dynavax sells an adult hepatitis B vaccine, Heplisav-B, which brought in $90 million in the third quarter of 2025. The California biotech has previously said it expects full-year 2025 revenues of $315 million to $325 million for the shot. According

Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price on December 23, 2025 EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Nasdaq: DVAX), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi's presence in adult immunization by bringin

New Delhi: India is considering waiving customs duty on pharmaceutical products made in special economic zones and sold in the domestic tariff area, a move that would allow drugmakers in these zones to supply vaccines and other critical medicines locally without paying the current 10% levy, people familiar with the matter said. The proposal, aimed at lowering costs and boosting domestic availability of essential drugs, may be announced in the Union budget for FY27, they said. "There is a thinkin

Sanofi announced Tuesday an agreement to acquire Dynavax Technologies for $15.50 per share in cash, or approximately $2.2 billion, adding an approved hepatitis B vaccine to its portfolio and a promising shot for shingles to its pipeline. The transaction — which represents a 39% premium over Dynavax's closing share price on December 23 — has been approved by the vaccine firm's board and is expected to close in the first quarter of 2026."Dynavax enhances Sanofi’s adult immunisation presence by add

Sanofi’s recent string of bad luck with tolebrutinib continues, with the company announcing Wednesday that the FDA declined to approve its application seeking approval of the oral brain-penetrant BTK inhibitor to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adults.Just last week, the French drugmaker said the FDA had delayed the target action date for the investigational drug in nrSPMS a second time, following an earlier postponement from Sep. 28 to Dec. 28.Houman Ash

The FDA on Wednesday approved Omeros' inhibitor Yartemlea (narsoplimab-wuug) for transplant-associated thrombotic microangiopathy (TA-TMA), making it the first therapy specifically cleared for the life-threatening complication of haematopoietic stem-cell transplantation.Driven by activation of the complement system's lectin pathway, the condition can develop after any stem-cell transplant, but it is more common following allogeneic procedures than autologous ones. Recent studies suggest TA-TMA s